Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open-Label Study of IMSB301 in Subjects With a Type 1 Interferonopathy

NCT07364513 is registered in ClinicalTrials.gov with ImmuneSensor Therapeutics Inc. as lead sponsor.

NCT NCT07364513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07364513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open-Label Study of IMSB301 in Subjects With a Type 1 Interferonopathy
Lead sponsor
ImmuneSensor Therapeutics Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
January 12, 2026
Completion date
July 30, 2026
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 interferonopathies